NZ769008A - Compositions and methods for treating cns disorders - Google Patents

Compositions and methods for treating cns disorders

Info

Publication number
NZ769008A
NZ769008A NZ769008A NZ76900815A NZ769008A NZ 769008 A NZ769008 A NZ 769008A NZ 769008 A NZ769008 A NZ 769008A NZ 76900815 A NZ76900815 A NZ 76900815A NZ 769008 A NZ769008 A NZ 769008A
Authority
NZ
New Zealand
Prior art keywords
methods
compositions
cns disorders
treating cns
present
Prior art date
Application number
NZ769008A
Other languages
English (en)
Inventor
Francesco Salituro
Botella Gabriel Martinez
Boyd Harrison
Albert Robichaud
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55747445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ769008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Priority claimed from NZ731034A external-priority patent/NZ731034B2/en
Publication of NZ769008A publication Critical patent/NZ769008A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ769008A 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders NZ769008A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064961P 2014-10-16 2014-10-16
NZ731034A NZ731034B2 (en) 2015-10-16 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
NZ769008A true NZ769008A (en) 2024-03-22

Family

ID=55747445

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ769008A NZ769008A (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders

Country Status (21)

Country Link
US (7) US10577390B2 (enExample)
EP (3) EP3206494A4 (enExample)
JP (4) JP6909155B2 (enExample)
KR (2) KR20230170816A (enExample)
CN (7) CN117024502A (enExample)
AR (1) AR102306A1 (enExample)
AU (5) AU2015331749A1 (enExample)
BR (1) BR112017007902B1 (enExample)
CA (1) CA2964766A1 (enExample)
CO (1) CO2017004649A2 (enExample)
IL (3) IL291533B2 (enExample)
JO (1) JO3724B1 (enExample)
MX (3) MX2021004492A (enExample)
MY (1) MY190408A (enExample)
NZ (1) NZ769008A (enExample)
PE (1) PE20170925A1 (enExample)
PH (2) PH12021550427A1 (enExample)
RU (2) RU2020131091A (enExample)
SG (3) SG11201703073UA (enExample)
TW (3) TWI762436B (enExample)
WO (1) WO2016061527A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RS60420B1 (sr) 2013-04-17 2020-07-31 Sage Therapeutics Inc 19-nor neuroaktivni steroidi za metode lečenja
AU2014256229B2 (en) 2013-04-17 2018-10-04 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
JP6466942B2 (ja) 2013-08-23 2019-02-06 セージ セラピューティクス， インコーポレイテッド 向神経活性ステロイド、組成物、及びその使用
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
JP7049313B2 (ja) * 2016-07-11 2022-04-06 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
NZ791594A (en) 2016-08-23 2025-08-29 Sage Therapeutics Inc A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
TWI620545B (zh) * 2017-01-20 2018-04-11 長青生醫科技股份有限公司 生物參數量測方法及其裝置
ES2914355T3 (es) 2017-08-07 2022-06-09 Alkermes Inc Inhibidores bicíclicos de la histona desacetilasa
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
ES2991092T3 (es) * 2017-12-22 2024-12-02 Sage Therapeutics Inc Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC
AR114044A1 (es) * 2017-12-22 2020-07-15 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
ES3018614T3 (es) * 2018-02-11 2025-05-16 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores derivados de esteroides, método para prepararlos y usos de los mismos
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11634453B2 (en) * 2018-10-12 2023-04-25 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
EP3867261B1 (en) * 2018-10-19 2025-04-30 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
CN109369762B (zh) * 2018-10-31 2021-06-18 湖南玉新药业有限公司 17-甲酸甾族化合物的制备方法
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
TWI874337B (zh) 2018-12-05 2025-03-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
AU2019397565A1 (en) * 2018-12-14 2021-07-08 Praxis Precision Medicines, Inc. Methods for the treatment of depression
CN113226326B (zh) * 2018-12-17 2024-09-20 细胞内治疗公司 有机化合物
JP7692830B2 (ja) * 2018-12-21 2025-06-16 セージ セラピューティクス， インコーポレイテッド ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
EP3909967A4 (en) * 2019-01-08 2022-11-09 Chengdu Kanghong Pharmaceutical Co., Ltd. STEROID COMPOUND AND USE THEREOF AND METHOD OF MANUFACTURE THEREOF
EP3934655A4 (en) * 2019-03-04 2022-12-21 Praxis Precision Medicines, Inc. PERIMENOPAUSE AND MENOPAUSE TREATMENT METHODS
CR20240234A (es) * 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
TWI896547B (zh) * 2019-06-27 2025-09-11 美商賽吉醫療公司 用於治療cns病症之組合物及方法
KR20220103707A (ko) * 2019-09-30 2022-07-22 엘리엄 테라퓨틱스 (유케이) 엘티디 Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
AU2020358002A1 (en) * 2019-10-02 2022-04-21 Praxis Precision Medicines, Inc. Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
PE20221911A1 (es) * 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
US20230210870A1 (en) * 2020-06-08 2023-07-06 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
WO2022040545A1 (en) * 2020-08-20 2022-02-24 Intra-Cellular Therapies, Inc. Organic compounds
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)
WO2022072620A1 (en) * 2020-10-01 2022-04-07 Eliem Therapeutics (UK) Ltd Methods of treating fibromyalgia with neuroactive steroids
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
US20220296613A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Food-independent dosing of cv-10155 to treat gabaa disorders
US20220296614A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
US20250170149A1 (en) 2022-02-28 2025-05-29 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2023211856A1 (en) * 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
WO2024189061A1 (en) 2023-03-14 2024-09-19 Curia Spain, S.A.U. Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids
CN116574150A (zh) * 2023-04-27 2023-08-11 广州楷石医药有限公司 一种二氢睾酮及其中间体的制备方法
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3983111A (en) * 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993005786A1 (en) 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
AU3075792A (en) 1991-11-14 1993-06-15 Stanley Poler Secondary eye growth impeding device and method
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
ATE195654T1 (de) * 1994-02-14 2000-09-15 Euro Celtique Sa Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
JP2002500616A (ja) 1994-07-21 2002-01-08 ファルマシア・アンド・アップジョン・カンパニー 神経学的に活性なアミノステロイド
DE69519945T2 (de) 1994-11-23 2001-06-07 Cocensys, Inc. Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
YU77701A (sh) * 1999-04-29 2005-07-19 Euro-Celtique S.A. 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
ES2243442T3 (es) 2000-02-18 2005-12-01 Taiho Pharmaceutical Company Limited Procedimiento de preparacion de derivados esteroides.
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
JP2004518637A (ja) 2000-11-03 2004-06-24 ワシントン・ユニバーシティ 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
AU2004224053B2 (en) 2003-03-24 2011-06-09 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
AU2004292555A1 (en) 2003-11-24 2005-06-09 Merck & Co., Inc. Estrogen receptor modulators
WO2005105822A2 (en) * 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP1807118B8 (en) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
EP1888080B1 (en) * 2005-06-09 2010-04-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
AU2008265898B2 (en) 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010054158A2 (en) 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US20130303500A1 (en) 2010-07-30 2013-11-14 Medexis S.A. Compounds and methods for treating neoplasia
WO2012083090A2 (en) 2010-12-15 2012-06-21 Harbor Biosciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
EP2675822A4 (en) 2011-02-15 2014-07-30 Socpra Sciences Et Génie S E C STEROID ALKALOIDS AND THEIR USE AS ANTIMICROBIAL AGENTS AGAINST MICROORGANISMS WITH ELECTRON TRANSPORT FAILURE AND AS MICROBIAL AGENT EXHAUSTERS AGAINST PATHOGENIC BACTERIA
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2987866B1 (en) 2011-03-23 2017-12-06 Etsuro Ito Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
NZ773177A (en) 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP6542127B2 (ja) 2012-12-18 2019-07-10 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
RS60420B1 (sr) 2013-04-17 2020-07-31 Sage Therapeutics Inc 19-nor neuroaktivni steroidi za metode lečenja
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
AU2014256229B2 (en) 2013-04-17 2018-10-04 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
JP6466942B2 (ja) 2013-08-23 2019-02-06 セージ セラピューティクス， インコーポレイテッド 向神経活性ステロイド、組成物、及びその使用
EP4144746A1 (en) 2014-05-29 2023-03-08 Sage Therapeutics, Inc. Neuroactive steroids, compositions and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
HUE051488T2 (hu) 2014-10-16 2021-03-01 Sage Therapeutics Inc Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
JP2018526423A (ja) 2015-09-08 2018-09-13 ビューポイント セラピューティクス， インコーポレイテッド 眼科疾患を処置するための化合物および製剤
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP3377070A4 (en) 2015-11-20 2019-07-10 Sage Therapeutics, Inc. COMPOUNDS AND METHOD FOR THEIR USE
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
JP7049313B2 (ja) 2016-07-11 2022-04-06 セージ セラピューティクス， インコーポレイテッド Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
NZ791594A (en) 2016-08-23 2025-08-29 Sage Therapeutics Inc A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
MX2020001732A (es) 2017-08-31 2020-03-20 Takeda Pharmaceuticals Co Tratamiento de las afecciones del sistema nervioso central.
EP3678670A1 (en) 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
AU2018364659A1 (en) 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
CN112823164A (zh) 2018-05-04 2021-05-18 阿克罗斯制药公司 神经甾体衍生物和其用途
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US10857163B1 (en) * 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Also Published As

Publication number Publication date
RU2017116732A (ru) 2018-11-16
JP6909155B2 (ja) 2021-07-28
US20230113666A1 (en) 2023-04-13
AR102306A1 (es) 2017-02-15
JP7012119B2 (ja) 2022-02-10
AU2020202892B2 (en) 2021-08-26
JP2020128420A (ja) 2020-08-27
US20170240589A1 (en) 2017-08-24
US11542297B2 (en) 2023-01-03
JP2022009567A (ja) 2022-01-14
CN118344424A (zh) 2024-07-16
EP4527461A2 (en) 2025-03-26
PH12017500711A1 (en) 2017-10-09
PH12021550427A1 (en) 2022-11-07
EP3206494A1 (en) 2017-08-23
US20220220150A1 (en) 2022-07-14
EP4527461A3 (en) 2025-06-25
NZ731034A (en) 2024-02-23
MX2021004492A (es) 2022-12-05
US12065463B2 (en) 2024-08-20
SG10202009861SA (en) 2020-11-27
EP3885352B1 (en) 2024-11-27
PH12017500711B1 (en) 2022-12-09
US20240368213A1 (en) 2024-11-07
EP3206494A4 (en) 2018-07-04
KR20170065661A (ko) 2017-06-13
TW202426002A (zh) 2024-07-01
CN112940066A (zh) 2021-06-11
JP7455098B2 (ja) 2024-03-25
CO2017004649A2 (es) 2017-11-10
US20200392177A1 (en) 2020-12-17
AU2020202892A1 (en) 2020-05-21
CN117024501A (zh) 2023-11-10
JP7692944B2 (ja) 2025-06-16
US20220213137A1 (en) 2022-07-07
AU2015331749A1 (en) 2017-05-04
CA2964766A1 (en) 2016-04-21
KR102612943B1 (ko) 2023-12-13
IL315006A (en) 2024-10-01
SG11201703073UA (en) 2017-05-30
MX2017005002A (es) 2018-01-23
US10577390B2 (en) 2020-03-03
IL291533B1 (en) 2024-09-01
US20190177358A1 (en) 2019-06-13
CN117024502A (zh) 2023-11-10
RU2733756C2 (ru) 2020-10-06
WO2016061527A1 (en) 2016-04-21
TW202235090A (zh) 2022-09-16
AU2021218132B2 (en) 2024-05-23
IL251721A0 (en) 2017-06-29
TW201629082A (zh) 2016-08-16
MX2021008583A (es) 2021-08-11
TWI762436B (zh) 2022-05-01
JP2017531019A (ja) 2017-10-19
IL291533B2 (en) 2025-01-01
JO3724B1 (ar) 2021-01-31
CN118344423A (zh) 2024-07-16
BR112017007902B1 (pt) 2023-12-05
MY190408A (en) 2022-04-21
CN112961206A (zh) 2021-06-15
AU2024202959A1 (en) 2024-05-23
PE20170925A1 (es) 2017-07-13
EP3885352A1 (en) 2021-09-29
JP2023071871A (ja) 2023-05-23
IL291533A (en) 2022-05-01
IL251721B (en) 2022-04-01
US11530237B2 (en) 2022-12-20
RU2020131091A (ru) 2020-11-23
BR112017007902A2 (pt) 2018-11-06
MX384728B (es) 2025-03-14
KR20230170816A (ko) 2023-12-19
CN107404877A (zh) 2017-11-28
RU2017116732A3 (enExample) 2019-02-28
AU2024213161A1 (en) 2024-09-12
AU2021218132A1 (en) 2021-09-09
TWI869654B (zh) 2025-01-11
SG10202009859YA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
MX2021008583A (es) Composiciones para el tratamiento de trastornos del snc.
NZ769042A (en) Compositions and methods for treating cns disorders
NZ749664A (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
WO2015010054A3 (en) Neuroactive steroids, compositions, and uses thereof
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
CR20200152A (es) DERIVADOS DE INDOL MONO-O-DI-SUSTITUIDOS COMO INHIBIDORES DE LA REPLICACIÓN VIRAL DEL DENGUE (Divisonal 2017-0490)
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12016502355A1 (en) Pharmaceutical composition
MY197698A (en) Oxysterols and methods of use thereof
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
HK1217092A1 (zh) 治疗性化合物及其用途
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX362879B (es) Usos novedosos.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
IN2013MU03838A (enExample)
HK1224586A1 (en) Neuroactive steroids, compositions, and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829